Kifunensine

立即咨询

Kifunensine

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

109944-15-2

包装与价格：

包装	价格(元)
1mg	电议
5mg	电议
10mg	电议
50mg	电议

产品介绍

化学性质

Physical Appearance	A crystalline solid
Storage	Store at -20°C
M.Wt	232.19
Cas No.	109944-15-2
Formula	C₈H₁₂N₂O₆
Solubility	Soluble in H2O
Chemical Name	(5R,6R,7S,8R,8aS)-6,7,8-trihydroxy-5-(hydroxymethyl)hexahydroimidazo[1,2-a]pyridine-2,3-dione
Canonical SMILES	VO[C@@H]([C@H]1O)[C@@H](NC2=O)N(C2=O)[C@H](CO)[C@H]1O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Kifunensine is a potent and selective inhibitor of class I α-mannosidases and may serve as a key inhibitor of glycoprotein biosynthesis[1]. Kifunensine inhibits both human endoplasmic reticulum α-1,2-mannosidase I and members of the Golgi subfamily of the class I mannosidases (Golgi α-mannosidase IA, IB, and IC) exhibiting Ki values of 130 and 23 nM, respectively. It also inhibits mung bean α-1,2-mannosidase I with an IC50 value of 20-50 nM[1]. Kifunensine can be used to block α-mannosidase I activity at the endoplasmic reticulum (ER), preventing the removal of desired mutated proteins through ER quality control mechanisms[2,3].

References:

[1]. Hering K W, Karaveg K, Moremen K W, et al. A Practical Synthesis of Kifunensine Analogues as Inhibitors of Endoplasmic Reticulum alpha-Mannosidase I. Journal of Organic Chemistry, 2005, 70(24): p.9892-9904.

[2]. Bartoli M, Gicquel E, Barrault L, et al. Mannosidase I inhibition rescues the human α-sarcoglycan R77C recurrent mutation. Human Molecular Genetics, 2008, 17(9): 1214-1221.

[3]. Soheili T, Gicquel E, Poupiot J, et al. Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications. Human Mutation, 2012, 33(2): 429-439.

试验操作

Cell experiment:[1]
Cell lines	Hybridoma cells expressing a human IgG1 monoclonal antibody against a tumor vascular associated antigen
Reaction Conditions	2 μg/mL kifunensine for 4 d incubation
Applications	Kifunensine treatment significantly reduced the lentil lectin binding. Furthermore, kifunensine was the most effective among the glycosylation inhibitors tested in producing antibodies containing oligomannose residues without fucose.
Animal experiment:[1]
Animal models	BALB/c mice
Dosage form	5 mg/kg Injected via the tail vein
Applications	The serum levels of antibody in mice were not significantly altered up to 168 h following injection. The use of kifunensine provided a simple and rapid method for the production of antibodies with increased antibody-dependent cell mediated cytotoxicity (ADCC) without the time-consuming need to re-engineer either the antibody molecule or the host cell line.
Note	The technical data provided above is for reference only.
	References: 1. Zhou Q, Shankara S, Roy A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnology and Bioengineering, 2008, 99(3): 652-665.